A randomized, double-blinded, placebo-controlled single ascending dose study evaluating the safety, pharmacokinetics and pharmacodynamics of CRN04777 in healthy volunteers
Latest Information Update: 27 Jan 2023
At a glance
- Drugs CRN 04777 (Primary)
- Indications Congenital hyperinsulinism
- Focus Adverse reactions; Pharmacokinetics
- 27 Jan 2023 New trial record